Twitxy Saved

Reptides

This account is verified because it's an official organization on X. Learn more

@reptidesco

The Intelligence layer for research
310 compounds ranked S-F on the clinical evidence
Proudly used by +10,000 biohackers/month.
reptides.co Joined June 2026
2 Following 4.1K Followers 752 Posts

Latest posts 5

Pinned post

Reptides @reptidesco
The peptide industry is a sales floor...

Affiliate codes, influencer hype, vendors selling, doctors selling.

All peptide information right now is a marketing funnel.

Reptides is the evidence layer.

And for $100 you get unlimited access, for a lifetime.

To an ever evolving research platform.
8 replies 3 reposts 33 likes 9.6K views View on X
Reptides @reptidesco
Altimmune ($ALT) reported Nov 9 that 42.2% of patients receiving pemvidutide achieved zero heavy-drinking days at week 24, versus 17.4% on placebo.

The RECLAIM Phase 2 trial tested the GLP-1/glucagon peptide in alcohol use disorder:

> Approximately 100 participants followed for 24 weeks
> Both groups also received standardized behavioral support
> Heavy-drinking days declined by 4.20 days per week vs 2.75 with placebo
> The percentage of abstinent days increased to 38.9% vs 20.5% with placebo

Altimmune plans to meet with the FDA in December to discuss a Phase 3 program for alcohol use disorder.
Reptides @reptidesco
Eli Lilly ($LLY) reported Nov 9 that its GLP-1 pill Foundayo reduced sleep-apnea breathing interruptions by 43.8% in trial participants not using PAP therapy.

The Phase 3 ATTAIN-OSA program studied adults with sleep apnea and obesity or overweight:

> Two studies involving 712 participants, followed for 52 weeks
> Breathing interruptions fell 43.8% with Foundayo vs 6.3% with placebo in the non-PAP group
> 31.5% of Foundayo patients in that group reached remission or mild disease
> Average weight loss in that group was 11.5% vs 1.8% with placebo

Lilly plans to seek FDA approval for Foundayo in sleep apnea by the end of 2026.
Reptides @reptidesco
Merck ($MRK) reported Nov 9 that its experimental peptide efinopegdutide achieved MASH resolution without worsening liver scarring in up to 63% of patients, versus 13% on placebo.

The Phase 2b trial tested the GLP-1/glucagon peptide in MASH, an inflammatory form of fatty liver disease:

> 381 adults were randomized and treated over 52 weeks
> The 7 mg group achieved the 63% MASH-resolution response
> At that dose, 52% also improved liver scarring without worsening MASH, versus 21% on placebo
> Side effects included nausea, diarrhea and vomiting

The findings were presented at The Liver Meeting and published in The Lancet. Efinopegdutide remains investigational.
Reptides @reptidesco
Argenx ($ARGX) announced a deal worth up to $1.15B to acquire peptide developer Unnatural Products on Nov 9.

The acquisition would add a macrocyclic peptide discovery platform to its immunology business:

> $550M upfront
> Up to another $595M tied to development and regulatory milestones
> Potential applications in oral and long-acting treatments for immune diseases
> Unnatural Products' team would continue operating from Santa Cruz, California

The deal is expected to close by the end of 2026, subject to customary conditions.